Bibliography: International Policy Issues

This document is an update of the International Cooperation Strategy adopted in 2007. It sets priorities in the area of the international cooperation aligned with the Centre’s Strategy 2025

This document is an update of the International Cooperation Strategy adopted in 2007. It sets priorities in the area of the international cooperation aligned with the Centre’s Strategy 2025 (EMCDDA)

This document is an update of the International Cooperation Strategy adopted in 2007. It sets priorities in the area of the international cooperation aligned with the Centre’s Strategy 2025

Global Drug Survey runs the largest drug survey in the world. Over half a million people have taken part in our last 5 surveys. This year, GDS2019 is translated into 20 languages and with partners in over 35 countrie.

International Drug Policy Consortium (IDPC) has produced this Shadow Report, to contribute constructively to high-level discussions on the next decade in global drug policy

It is time to make special efforts to provide public services and support to people who use drugs and communities that have been harmed by the so-called war on drugs. It is time to rethink the overall goals of drug policies to ensure that they are aligned with the Sustainable Development Agenda (GCDP)

The evidence-based multi-criteria drug harm scale (MCDHS) has been proposed as a way of grounding policy in the actual degree of harmfulness of drugs … This article reviews strengths and weaknesses of evidence provided with the use of MCDHS. Furthermore, the author argues that the shortcomings of MCDHS can be resolved by offering methodological improvements (Frontiers in Pharmacology)

The General Report of Activities is an annual publication providing a detailed progress report of the EMCDDA’s activities over a 12-month period. It catalogues the Centre’s achievements in each area of its annual work programme. The report is a useful information source for all those seeking comprehensive information on the Centre and its work (EMCDDA)

The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2018 European Drug Report package English (EMCDDA)

he EMCDDA Programming Document for the period 2018–20 covers the final year of implementation of the EMCDDA Strategy 2016–18 and coincides with the completion of the first Roadmap established under the new EMCDDA Strategy 2025

Report by the expert group on possible adverse effects and associated costs of drug control policies (Pompidou Group)

SIGAR’s quarterly report to US Congress

Beyond traditional indicators? (GDPO)

The present report aims to analyze the most common perceptions and fears, contrast them with available evidence on drugs and the people who use them, and provides recommendations on changes that must be enacted to support reforms toward more effective drug policies (The Global Commission on Drug Policy)

In May 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), through a joint assessment (EMCDDA)

Covering activities during 2016

Health and social responses to drug problems: a European guide is designed to provide an overview of actions or interventions undertaken to address the negative consequences associated with the illicit drug phenomenon (EMCDDA)

This document summarises the main issues concerning evaluation in the field of drug policy. Aimed at those managing rather than undertaking drug policy evaluations, the guide acts as an introduction, providing links to the wider literature (EMCDDA)

To support those considering or involved in commissioning, managing or undertaking policy evaluations, this provides access to a range of materials, including a 7-step guide, examples of strategies and evaluations in Europe and potentially useful data sources (EMCDDA)

This week, the EU has reacted to serious concerns over the use of the synthetic opioid acryloylfentanyl by deciding to subject it to ‘control measures’ throughout the Union (EMCDDA)

Beginning with an overview of the synthetics market, this Policy Report examines the possible sources of such inertia and critically explores the issues underlying what in many respects represents a key yet largely under discussed feature of the extant international drug control system (GDPO)

The two bodies recognise that information on the drug phenomenon is an essential and indispensable instrument for drafting and implementing drug policies and for assessing the impact of actions to reduce problems originating from drug use and trafficking

The Plan sets out the Actions that will be implemented to achieve the objectives of the Strategy (EUR-Lex)

This report presents the key activities performed by the EMCDDA and Europol in 2016 and the results of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances, including new psychoactive substances notified in 2016 (EMCDDA)